Skip to main content

Advertisement

Articles

Page 4 of 6

  1. Temsirolimus, a selective inhibitor of the mammalian target of rapamycin, has demonstrated clinical benefit versus investigator’s choice (INV) of therapy in patients with relapsed/refractory mantle cell lympho...

    Authors: Georg Hess, Bertrand Coiffier, Michael Crump, Christian Gisselbrecht, Fritz Offner, Jorge Romaguera, Lisa Kang and Pádraig J Moran

    Citation: Experimental Hematology & Oncology 2015 4:11

    Content type: Research

    Published on:

  2. The aim of this study was to elucidate the mechanisms responsible for the location of B-cell non-Hodgkin’s lymphoma (B-NHL) at different anatomical sites. We speculated that the malignant B cells in these diso...

    Authors: Stephen Middle, Sarah E Coupland, Azzam Taktak, Victoria Kidgell, Joseph R Slupsky, Andrew R Pettitt and Kathleen J Till

    Citation: Experimental Hematology & Oncology 2015 4:10

    Content type: Research

    Published on:

  3. Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocyte...

    Authors: Seong-Su Han, Van S Tompkins, Dong-Ju Son, Sangwoo Han, Hwakyung Yun, Natalie L Kamberos, Casey L Dehoedt, Chunyan Gu, Carol Holman, Guido Tricot, Fenghuang Zhan and Siegfried Janz

    Citation: Experimental Hematology & Oncology 2015 4:9

    Content type: Research

    Published on:

  4. A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and rituximab, which produced a complete remission. Eight months after the last dose of rituximab he ha...

    Authors: Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría, Juan M Sepúlveda and Juan F García

    Citation: Experimental Hematology & Oncology 2015 4:8

    Content type: Case report

    Published on:

  5. The role of platelets extends beyond hemostasis. The pivotal role of platelets in inflammation has shed new light on the natural history of conditions associated with acute or chronic inflammation. Beyond the ...

    Authors: Antoine Dewitte, Annabelle Tanga, Julien Villeneuve, Sébastien Lepreux, Alexandre Ouattara, Alexis Desmoulière, Christian Combe and Jean Ripoche

    Citation: Experimental Hematology & Oncology 2015 4:6

    Content type: Review

    Published on:

  6. Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of...

    Authors: Jesper Kofoed Damm, Sandra Gordon, Mats Ehinger, Mats Jerkeman, Urban Gullberg, Anne Hultquist and Kristina Drott

    Citation: Experimental Hematology & Oncology 2015 4:4

    Content type: Rapid communication

    Published on:

  7. Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castlem...

    Authors: Silvia Tedesco, Laura Postacchini, Lucia Manfredi, Gaia Goteri, Michele M Luchetti, Antonella Festa, Armando Gabrielli and Giovanni Pomponio

    Citation: Experimental Hematology & Oncology 2015 4:3

    Content type: Case report

    Published on:

  8. Because up to 30% of breast cancer cases may relapse, understanding the biology of recurrent breast cancer is imperative in preventing these poor outcomes. Thus, we present this unusual case of a BRCA2 carrier...

    Authors: Polly Niravath, Tanya Eble, Alejandro Contreras, Marilyn Li, Luis M Franco and Mothaffar Rimawi

    Citation: Experimental Hematology & Oncology 2015 4:1

    Content type: Case report

    Published on:

  9. The combination of rituximab and 2-CdA is an effective therapy for B-cell tumors. However, the molecular mechanisms and enzymatic pathways involved in the interaction between the two agents are not fully under...

    Authors: Ayad M Al-Katib, Amro Aboukameel, AbdulShukkur Ebrahim, Frances WJ Beck, Samuel E Tekyi-Mensah, Ali Raufi, Yasin Ahmed, Mary Mandziara and Zyad Kafri

    Citation: Experimental Hematology & Oncology 2014 3:31

    Content type: Research

    Published on:

  10. Tissue factor (TF) exposed on activated monocytes and macrophages is involved in thrombosis through activation of factor X and cytokine release, responsible for inflammation and thrombosis. We investigated the...

    Authors: Marc Laurent, Ulrich Joimel, Rémi Varin, Lionel Cazin, Caroline Gest, Veronique Le-Cam-Duchez, Jian Jin, Jielin Liu, Jean-Pierre Vannier, He Lu, Jeannette Soria, Hong Li and Claudine Soria

    Citation: Experimental Hematology & Oncology 2014 3:30

    Content type: Research

    Published on:

  11. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite the use of optimized first-line therapy, GBM is still associated with a poor prognosis and an effective second-...

    Authors: Katrin Schweneker, Christoph Clemm, Melanie Brügel, Michael Souvatzoglou, Mirjam Hermisson, Friederike Schmidt-Graf, Claus Zimmer, Christian Peschel and Philipp J Jost

    Citation: Experimental Hematology & Oncology 2014 3:29

    Content type: Case report

    Published on:

  12. T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive subtype of chronic lymphocytic leukemia. Usually it presents in older people with a median age of 61 years. T-PLL is characterized by elevated wh...

    Authors: Abdulsamad Wafa, Abdulmunim Aljapawe, Moneeb AK Othman, Thomas Liehr, Eyad Alhourani and Walid Al Achkar

    Citation: Experimental Hematology & Oncology 2014 3:28

    Content type: Case report

    Published on:

  13. We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselect...

    Authors: Teresa Moran, Enriqueta Felip, Vicki Keedy, Hossein Borghaei, Frances A Shepherd, Amelia Insa, Holly Brown, Timothy Fitzgerald, Sriram Sathyanarayanan, John F Reilly, David Mauro, Karl Hsu, Li Yan and David H Johnson

    Citation: Experimental Hematology & Oncology 2014 3:1

    Content type: Research

    Published on:

  14. Tobacco, alcohol and HPV infection are associated with increased risk of HNSCC. However, little is known about the underlying signaling events influencing risk. We aimed to investigate the relationship between...

    Authors: Mohammad R Islam, Ian R Ellis, Michaelina Macluskey, Lynda Cochrane and Sarah J Jones

    Citation: Experimental Hematology & Oncology 2014 3:25

    Content type: Research

    Published on:

  15. Cholesterol plays an important role in cancer development, drug resistance and chemoimmuno-sensitivity. Statins, cholesterol lowering drugs, can induce apoptosis, but also negatively interfere with CD-20 and r...

    Authors: Indira Benakanakere, Tyler Johnson, Richard Sleightholm, Virgilio Villeda, Monika Arya, Ravi Bobba, Carl Freter and Chunfa Huang

    Citation: Experimental Hematology & Oncology 2014 3:24

    Content type: Research

    Published on:

  16. Hormone-refractory breast cancer metastatic to bone is a clinically challenging disease associated with high morbidity, poor prognosis, and impaired quality of life owing to pain and skeletal-related events. I...

    Authors: Amol Takalkar, Scott Adams and Vivek Subbiah

    Citation: Experimental Hematology & Oncology 2014 3:23

    Content type: Short report

    Published on:

  17. Little is known about the epidemiology of MDS in minority populations. The IPSS and newly released IPSS-R are important clinical tools in prognostication of patients with MDS. Therefore, we conducted a retrosp...

    Authors: Ashwin Sridharan, Rishi Jain, Marcus A Bachhuber, Yiting Yu, KH Ramesh, Krishna Gundabolu, Ellen W Friedman and Amit K Verma

    Citation: Experimental Hematology & Oncology 2014 3:22

    Content type: Research

    Published on:

  18. Acquired hemophilia A (AHA) and acquired von Willebrand Syndrome (AVWS) are both rare bleeding disorders that can be associated with lymphoproliferative or autoimmune diseases. AHA is uniformly caused by inhib...

    Authors: Christina Dicke, Katharina Holstein, Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim, Carsten Bokemeyer, Christof Iking-Konert, Ulrich Budde and Florian Langer

    Citation: Experimental Hematology & Oncology 2014 3:21

    Content type: Case report

    Published on:

  19. Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old. This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, an...

    Authors: Elisa Rogowitz, Hani M Babiker, Mohammed Kanaan, Rebecca A Millius, Q Scott Ringenberg and Maria Bishop

    Citation: Experimental Hematology & Oncology 2014 3:20

    Content type: Case report

    Published on:

  20. Citation: Experimental Hematology & Oncology 2014 3:19

    Content type: Erratum

    Published on:

    The original article was published in Experimental Hematology & Oncology 2014 3:10

  21. Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) proliferation, rarely associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KITD816V is regarded as driver-mutation in SM...

    Authors: Markus Rechsteiner, Rouven Müller, Tanja Reineke, Jeroen Goede, Annette Bohnert, Qing Zhong, Markus G Manz, Holger Moch, Peter J Wild, Dieter R Zimmermann and Marianne Tinguely

    Citation: Experimental Hematology & Oncology 2014 3:18

    Content type: Rapid communication

    Published on:

  22. The miR-29 family have been demonstrated acting as vital tumor suppressor in multiple cancers as well as regulators in the adaptive immune system. Little is known about their role in leukemogenesis. The purpos...

    Authors: Ling Xu, Yan Xu, Zhenyi Jing, Xu Wang, Xianfeng Zha, Chengwu Zeng, Shaohua Chen, Lijian Yang, Gengxin Luo, Bo Li and Yangqiu Li

    Citation: Experimental Hematology & Oncology 2014 3:17

    Content type: Research

    Published on:

  23. In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent childhood hematological malignancy, as well as the leading cause of childhood cancer-related mortality. Advances in cyt...

    Authors: Jennifer S Woo, Michael O Alberti and Carlos A Tirado

    Citation: Experimental Hematology & Oncology 2014 3:16

    Content type: Review

    Published on:

  24. A 91-year-old woman affected with acquired Von Willebrand (VW) syndrome and intestinal angiodysplasias presented with severe gastrointestinal bleeding (hemoglobin 5 g/dl). Despite replacement therapy with VW f...

    Authors: Massimo Cugno, Alberto Tedeschi, Simona Maria Siboni, Francesca Stufano, Federica Depetri, Franca Franchi, Samantha Griffini and Flora Peyvandi

    Citation: Experimental Hematology & Oncology 2014 3:15

    Content type: Case report

    Published on:

  25. Recently, whole genome sequencing approaches have pinpointed mutations in genes that were previously not associated with cancer. For Acute Myeloid Leukaemia (AML), and other myeloid disorders, these approaches...

    Authors: Bryony Leeke, Judith Marsman, Justin M O’Sullivan and Julia A Horsfield

    Citation: Experimental Hematology & Oncology 2014 3:13

    Content type: Review

    Published on:

  26. Mesothelin, a mesothelial marker, has been found expressed in and as a potential treatment target of cholangioacarcinoma (CC). It is possible that CC may be derived from the cells sharing mesothelial markers. ...

    Authors: Lanjing Zhang, Renee Frank, Emma E Furth, Amy F Ziober, Virginia A LiVolsi and Paul J Zhang

    Citation: Experimental Hematology & Oncology 2014 3:12

    Content type: Research

    Published on:

  27. Recombinant human interleukin 12 (rHuIL-12) regulates hematopoiesis and cell-mediated immunity. Based on these hematopoietic and immunomodulatory activities, a recombinant human IL-12 (rHuIL-12) is now under d...

    Authors: Mamata S Gokhale, Vladimir Vainstein, Jamie Tom, Simmy Thomas, Chris E Lawrence, Zoya Gluzman-Poltorak, Nicholas Siebers and Lena A Basile

    Citation: Experimental Hematology & Oncology 2014 3:11

    Content type: Research

    Published on:

  28. This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment.

    Authors: B Douglas Smith, Charles L Beach, Dalia Mahmoud, Laura Weber and Henry J Henk

    Citation: Experimental Hematology & Oncology 2014 3:10

    Content type: Research

    Published on:

    The Erratum to this article has been published in Experimental Hematology & Oncology 2014 3:19

  29. Arsenic trioxide (ATO) is a novel form of therapy that has been found to aid acute promyelocytic leukemia (APL) patients. Our laboratory has demonstrated that ATO-induced cytotoxicity in human leukemia (HL-60)...

    Authors: Christian S Rogers, Clement G Yedjou, Dwayne J Sutton and Paul B Tchounwou

    Citation: Experimental Hematology & Oncology 2014 3:9

    Content type: Research

    Published on:

  30. The gene RUNX1 at chromosome 21q22 encodes the alpha subunit of Core binding factor (CBF), a heterodimeric transcription factor involved in the development of normal hematopoiesis. Translocations of RUNX1 are see...

    Authors: Jianling Ji, Eric Loo, Sheeja Pullarkat, Lynn Yang and Carlos A Tirado

    Citation: Experimental Hematology & Oncology 2014 3:8

    Content type: Case report

    Published on:

  31. Those stimuli that together promote the survival, differentiation and proliferation of the abnormal B-lymphocytes of chronic lymphocytic leukaemia (CLL) are encountered within tissues, where together they form...

    Authors: Claire V Hutchinson, Shiva Natarajan, Suzanne M Johnson, Julie A Adams, Karen S Rees-Unwin and John Burthem

    Citation: Experimental Hematology & Oncology 2014 3:7

    Content type: Research

    Published on:

  32. Here we report on a case of Philadelphia chromosome positive B lymphoblastic leukemia (Ph+ALL), which developed following a long duration of essential thrombocythemia (ET). A mutational analysis of Janus Kinase 2...

    Authors: Yuya Nagai, Masahiro Kawahara, Noriko Sugino, Yayoi Shimazu, Masakatsu Hishizawa, Kouhei Yamashita, Norimitsu Kadowaki and Akifumi Takaori-Kondo

    Citation: Experimental Hematology & Oncology 2014 3:6

    Content type: Case report

    Published on:

  33. Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) has been shown to work synergistically to increase apoptosis and cell cycle arrest in breast cancer cells. In this report, we further expl...

    Authors: Shundong Cang, Yuehua Ma, Jen-wei Chiao and Delong Liu

    Citation: Experimental Hematology & Oncology 2014 3:5

    Content type: Research

    Published on:

  34. Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell ma...

    Authors: Aileen Novero, Pavan M Ravella, Yamei Chen, George Dous and Delong Liu

    Citation: Experimental Hematology & Oncology 2014 3:4

    Content type: Review

    Published on:

  35. The host’s immune system is crucially involved in cancer development and progression. The ratio of regulatory to effector T-cells, as well as the interplay of T-cells with therapeutic agents, impact on cancer ...

    Authors: Anna Koumarianou, Maria-Ioanna Christodoulou, Pavlos Patapis, Iordanis Papadopoulos, Elissavet Liakata, Athina Giagini, Anastasia Stavropoulou, Nikiforita Poulakaki, Nikolaos Tountas, Nikolaos Xiros, Theophanis Economopoulos, Dimitris Pectasides, Ourania E Tsitsilonis and Vassiliki Pappa

    Citation: Experimental Hematology & Oncology 2014 3:3

    Content type: Research

    Published on:

  36. We analyze the epidemiological characteristics and outcomes of 72 patients diagnosed with non-metastatic inflammatory breast cancer (IBC) at National Institute of Oncology of Rabat in Morocco, between January ...

    Authors: Nabil Ismaili, Hind Elyaakoubi, Youssef Bensouda and Hassan Errihani

    Citation: Experimental Hematology & Oncology 2014 3:1

    Content type: Letter to the Editor

    Published on:

  37. The immune system is the built-in host defense mechanism against infectious agents as well as cancer. Protective immunity against cancer was convincingly demonstrated in the 1940s with syngeneic animal models ...

    Authors: Zihai Li, Lieping Chen and Mark P Rubinstein

    Citation: Experimental Hematology & Oncology 2013 2:33

    Content type: Review

    Published on:

  38. Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overa...

    Authors: James Signorovitch, Elyse Swallow, Evan Kantor, Xufang Wang, Judith Klimovsky, Tomas Haas, Beth Devine and Peter Metrakos

    Citation: Experimental Hematology & Oncology 2013 2:32

    Content type: Research

    Published on:

  39. Metaplastic breast cancer (MBC) is a rare subtype of invasive breast cancer that tends to have an aggressive clinical presentation as well as a variety of distinct histologic designations. Few systemic treatme...

    Authors: Theresa L Schwartz, Harveshp Mogal, Christos Papageorgiou, Jula Veerapong and Eddy C Hsueh

    Citation: Experimental Hematology & Oncology 2013 2:31

    Content type: Review

    Published on:

  40. Neoadjuvant therapy is an under-utilized regimen for the treatment of metastatic melanoma. The use of this approach has been increasing in other tumor types. Neoadjuvant therapy may reduce occult circulating t...

    Authors: Shachar Laks, Kevin A Brueske and Eddy C Hsueh

    Citation: Experimental Hematology & Oncology 2013 2:30

    Content type: Review

    Published on:

  41. Mast cell activation syndrome (MCAS) is a relatively recently recognized cause of chronic multisystem polymorbidity of a generally inflammatory theme. Patients with MCAS often report migratory soft tissue and/...

    Authors: Lawrence B Afrin

    Citation: Experimental Hematology & Oncology 2013 2:28

    Content type: Case report

    Published on:

  42. In diffuse large B-cell lymphomas, gene expression profiling studies attributed a major biologic role to non-neoplastic cells of the tumour microenvironment as its composition and characteristics were shown to...

    Authors: Simone Brandt, Chiara Montagna, Antoin Georgis, Peter J Schüffler, Marco M Bühler, Burkhardt Seifert, Thore Thiesler, Alessandra Curioni-Fontecedro, Ivan Hegyi, Silvia Dehler, Vittoria Martin, Marianne Tinguely and Davide Soldini

    Citation: Experimental Hematology & Oncology 2013 2:27

    Content type: Research

    Published on:

  43. Resistance to radiation treatment remains a major clinical problem for patients with brain cancer. Medulloblastoma is the most common malignant brain tumor of childhood, and occurs in the cerebellum. Though ra...

    Authors: Wendy J Ingram, Lisa M Crowther, Erica B Little, Ruth Freeman, Ivon Harliwong, Desi Veleva, Timothy E Hassall, Marc Remke, Michael D Taylor and Andrew R Hallahan

    Citation: Experimental Hematology & Oncology 2013 2:26

    Content type: Research

    Published on:

Annual Journal Metrics

On the blog

Advertisement